Year: 2026
Type: article
Study design: Clinical Trial
Abstract: PURPOSE: Drug response for cancer symptom management is variable. The purpose of this trial is to study the impact of multigene pharmacogenomic (PGx) testing on drug prescribing in supportive oncology. METHODS: This is a single-arm prospective trial of adults with cancer referred to the supportive oncology clinic with Edmonton Symptom Assessment System pain ≥ 4, depression ≥ 3, or requiring antidepressant modification. Patients were genotyped for variants in CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19, CYP2B6, COMT, OPRM1, SLC6A4, and HTR2A, and assessed every 4 weeks up to a maximum of 16 weeks. Primary endpoint was the proportion of patients with ≥ 1 PGx-guided intervention. Secondary endpoints included the type/frequency of drug-gene interactions (DGIs) at baseline and final visits, and the type/frequency of interruptive PGx alerts in the electronic health record (EHR). RESULTS: 70 patients were genotyped (54% female, 67% White, 33% Black, median age 59). Gynecologic (21%), breast (14%), and hematologic (14%) cancers were most common, and 64% had stage III or IV disease. 50% and 59% carried a CYP2D6 or CYP2C19 non-normal metabolizer phenotype, respectively. Of 66 evaluable patients, 9 (14%, 95% CI 7-24%) had a PGx-guided intervention, mostly for opioids and antidepressants. At baseline and final visits, 25 (n = 23; 35%) and 22 (n = 21; 32%) DGIs, respectively, were present. There were 26 interruptive alerts triggered for 10 (18%) of 56 patients evaluable for PGx alerts, mostly for CYP2C19-proton pump inhibitors (PPIs) and CYP2C19/CYP2B6-antidepressants. CONCLUSION: DGIs, mostly for opioids, antidepressants, and PPIs, were common and PGx-guided interventions occurred in a minority of patients. Interruptive alerts were frequent and prompted PGx-guided interventions in most patients with actionable interactions, highlighting the opportunity to optimize EHR-based clinical decision support.
Source: Supportive Care in Cancer
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Keywords: pharmacogenetic testing, cancer supportive care, cancer symptom management, drug-gene interactions, CYP2C19, CYP2D6, CYP2C9, CYP2B6, CYP3A4, CYP3A5, antidepressants, opioids, proton pump inhibitors, electronic health record alerts, clinical decision support, personalized medicine, pain, depression
Open Access status: hybrid
Estimated APC paid: $4,690
OpenAlex ID: W7236214757
